|
Categories |
|
Latest Reports |
|
|
Biotechnology
Cancer
Consumer
Customer
Relationship Management
Drug
Delivery
eHealthcare
Pharma
eHealthcare
Physician
Generics
Healthcare
Medical
Devices
OTC
Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic
Areas:
- Cardiovascular
- Central
Nervous System
- Immune
Disorders and Inflammation
- Infectious
Diseases
- Oncology
-
Women'sHealth
|
|
|
1- Merck & Co: PharmaVitae Profile 2005 17-Nov-2005 (Pharmaceutical)
This company analysis examines the current position and future outlook for Merck & Co in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
2-Boehringer Ingelheim: PharmaVitae Profile 2005 16-Nov-2005 (Pharmaceutical)
This analysis examines the current position and future outlook for Boehringer Ingelheim in the pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information..
------------------------------------------------------------------------------------------------------------------------- |
3- Pipeline and Commercial Insight: Alzheimer’s Disease - Beta treatments on the horizon 07-Nov-2005 (Central Nervous System)
Detailed analysis of the commercial opportunities and threats facing Alzheimer's disease therapeutics across the seven major markets, including a review of the late-stage development pipeline and sales forecasts for key drugs.
------------------------------------------------------------------------------------------------------------------------- |
4- PharmaVitae 2005: GlaxoSmithKline Global Analysis 17-Oct-2005 (Pharmaceutical)
This analysis examines the current position and future outlook for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
5- Stakeholder Insight: Prostate Cancer - A Prostrate Market Waiting for Innovations 11-Oct-2005 (Oncology)
Explores current treatment practices for hormone-sensitive and hormone-refractory prostate cancer in the seven major markets, based on primary research with 180 physicians, and examines key pipeline agents and potential regimens in 2010.
------------------------------------------------------------------------------------------------------------------------- |
6- The CNS Market Outlook to 2010 05-Oct-2005 (Central Nervous System)
CNS disorders contribute to as much as 35% of the disease burden in the seven major pharmaceutical markets (US, Japan, France, Germany, Italy, Spain and UK) as measured in terms of daily-adjusted life years.
------------------------------------------------------------------------------------------------------------------------- |
7-PharmaVitae 2005: Pfizer Global Analysis 03-Oct-2005 (Pharmaceutical)
This analysis examines the current position and future outlook for Pfizer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
8- Direct-to-Consumer Advertising Regulations in the US: What are the implications for the eHealth market? 16-Sep-2005 (eHealthcare)
Public perception of the US pharmaceutical industry is at an all-time low. Enhanced safety warnings attached to some drugs and the complete market withdrawal of others have undermined consumer confidence in both the industry and the products it produces. These doubts pose an imminent danger to an industry that will have to rely increasingly on word-of-mouth to create brand awareness and loyalty.
------------------------------------------------------------------------------------------------------------------------- |
9- Optimizing Targeted Treatment in Cancer: Negotiating the Challenges to Success 02-Sep-2005 (Oncology)
Drawing on the ideas and discussion generated by leading oncology experts, this Market Brief examines the clinical and commercial challenges facing developers, and strategies to meet them as the oncology market transitions into a new era.
------------------------------------------------------------------------------------------------------------------------- |
10- The Cardiovascular Market Outlook to 2010
01-Aug-2005 (Cardiovascular)
This report provides information on the prevalence and incidence of cardiovascular disease in the seven largest pharmaceutical markets in 2004, and provides forecast epidemiological data for major therapeutic indications over the period 2004 to 2010.
-------------------------------------------------------------------------------------------------------------------------
|
| |
